Biotechnology Cancer Cures Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Biotechnology Cancer Cures

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Mike McFarland who wrote (157)	5/18/2000 7:47:00 AM
From: david james	of 226

Yes, something is certainly baffling regarding Cell Genesys and its ties to Abgenix. Take a look at this chart. siliconinvestor.com In February, CEGE converted $200 mill of their ABGX stock to cash, and gave them a boost to briefly move above their book value, but since then they have fallen back to tracking ABGX. I can only assume their is some hedge fund out there that is trading ABGX against CEGE and shorting and/or buying one or the other when the two get out of alignment. Right now the street is giving no value to their science, despite the phase II cancer vaccines and their technology which should generate around $40 mill and with the interest on their cash, should be enough to for them to post a profit for the rest of the year. streetadvisor.com

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next